登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Med，6月5日，Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-06

  • Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19

    Author links open overlay panelJosephMagagnoliMS12∗SiddharthNarendranMD45∗FelipePereiraMD45∗Tammy H.CummingsPhD12James W.HardinPhD3S. ScottSuttonPharmD12JayakrishnaAmbatiMD4567

    Show more

    https://doi.org/10.1016/j.medj.2020.06.001

    Abstract

    Background

    Despite limited and conflicting evidence, hydroxychloroquine, alone or in combination with azithromycin, is widely used in COVID-19 therapy.

    Methods

    We performed a retrospective study of electronic health records of patients hospitalized with confirmed SARS-CoV-2 infection in United States Veterans Health Administration medical centers between March 9, 2020 and April 29, 2020. Patients hospitalized within 24 hours of diagnosis were classified based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) or no HC as treatments. The primary outcomes were mortality and use of mechanical ventilation.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S2666634020300064
64浏览量
原文链接
相关报告

  • 《6月5日_美国因COVID-19住院的退伍军人使用羟氯喹治疗的结果》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-07
    • 信息名称：美国因COVID-19住院的退伍军人使用羟氯喹治疗的结果 1.时间：2020年6月5日 2.机构或团队：南卡罗莱纳州哥伦比亚退伍军人卫生保健系统、南卡罗莱纳大学、弗吉尼亚大学 3.事件概要： 南卡罗莱纳州哥伦比亚退伍军人卫生保健系统等于6月5日在Med期刊上发表题为“Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19”的文章。文章指出，研究人员对2020年3月9日至2020年4月29日期间在美国退伍军人健康管理局医疗中心住院的确诊SARS-CoV-2感染患者的电子健康记录进行了回顾性研究。在诊断后24小时内住院的患者根据其单独使用羟氯喹（HC）、与阿奇霉素联合使用（HC+AZ）或不使用HC治疗的情况进行分类。主要结果是死亡率和机械通气的使用。研究发现，在COVID-19住院患者中，单独使用HC或HC与AZ联合使用都没有显著降低死亡率和对机械通气的需求。 4.附件： 原文链接： https://www.sciencedirect.com/science/article/pii/S2666634020300064
    75浏览量
    原文链接

  • 《MedRxiv，5月25日，Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-26
    • Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study View ORCID ProfileAndrew Ip, View ORCID ProfileDonald A Berry, Eric Hansen, View ORCID ProfileAndre H Goy, Andrew L Pecora, Brittany A Sinclaire, Urszula Bednarz, Michael Marafelias, Scott M Berry, Nicholas S Berry, Shivam Mathura, Ihor S Sawczuk, Noa Biran, View ORCID ProfileRonaldo C Go, Steven Sperber, Julia A Piwoz, Bindu Balani, Cristina Cicogna, Rani Sebti, Jason Zuckerman, Keith M Rose, Lisa Tank, Laurie Jacobs, Jason Korcak, Sarah L Timmapuri, Joseph P Underwood III, Gregory Sugalski, Carol Barsky, Daniel W Varga, Arif Asif, Joseph C Landolfi, View ORCID ProfileStuart L Goldberg doi: https://doi.org/10.1101/2020.05.21.20109207 Abstract Background: Hydroxychloroquine has been touted as a COVID-19 treatment. Tocilizumab, an inhibitor of IL-6, has been proposed as a treatment of critically ill patients. Objective: To describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Design: Retrospective observational cohort study of electronic health records Setting: 13-hospital network spanning the state of New Jersey. Participants: Patients hospitalized between March 1, 2020 and April 22, 2020 with positive polymerase chain reaction results for SARS-CoV-2. Follow up was through May 5, 2020. Main Outcomes: The primary outcome was death. Results: Among 2512 hospitalized patients with COVID-19 there have been 547 deaths (22%), 1539 (61%) discharges and 426 (17%) remain hospitalized. 1914 (76%) received at least one dose of hydroxychloroquine and 1473 (59%) received hydroxychloroquine with azithromycin. After adjusting for imbalances via propensity modeling, compared to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]). *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    85浏览量
    原文链接